share_log

Altimmune | 4: Statement of changes in beneficial ownership of securities-Officer Jordt Raymond M

SEC announcement ·  Feb 2 07:07
Summary by Futu AI
Raymond M. Jordt, the Chief Business Officer of Altimmune, Inc., completed a purchase of 5,030 shares of common stock on January 31, 2024. The transaction was carried out directly with shares acquired at a price of $2.69 each. Following this transaction, Jordt's direct holdings in the company increased to a total of 13,743 shares. The acquisition reflects a vested interest in the company's performance and is a notable financial move within Altimmune's corporate structure.
Raymond M. Jordt, the Chief Business Officer of Altimmune, Inc., completed a purchase of 5,030 shares of common stock on January 31, 2024. The transaction was carried out directly with shares acquired at a price of $2.69 each. Following this transaction, Jordt's direct holdings in the company increased to a total of 13,743 shares. The acquisition reflects a vested interest in the company's performance and is a notable financial move within Altimmune's corporate structure.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.